

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Unassigned
		Filing Date	August 4, 2003
		First Named Inventor	Martin OPPER et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	38005-0183
Sheet	3	of	4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KAC	A16	GILLIES et al; Human Antibodies Hybridomas; Vol. 1, No. 1; pp. 47-54, 1990	
	A17	AXELSSON; Acta Chemica Scandnavica Series B; Vol. 39, No. 1; pp. 69-77, 1985	
	A18	PAULUS et al.; Behring Inst. Mitt.; No. 78; pp. 118-132, 1985	
	A19	BURGESS et al.; Journal of Cell Biology; Vol. 111; pp. 2129-2138, 1990	
	A20	LASAR et al; Molecular and Cellular Biology; Vol. 8, No. 3; pp. 1247-1252, 1988	
	A21	SCHWARTZ et al.; Proc. Natl. Acad. Sci. USA; Vol. 84; pp. 6408-6411, 1987	
	A22	LIN et al.; Biochemistry USA; Vol. 14; pp. 1559-1563, 1975	
	A23	HAISMA et al., "A monoclonal antibody- B-glucuronidase conjugate as a activator of the prodrug epirubicin-glucuronide for specific treatment of cancer", Br. J. Cancer, pp. 474-478, September 1992, Vol. 66, No. 3	
	A24	HE et al., "Functional expression of a single-chain anti-progesterone antibody fragment in the cytoplasm of a mutant Escherichia coli", Nucleic Acids Research, pp. 4009-4010, 1995, Vol. 23, No. 19, Oxford University Press	
↓	A25	QUI, J., Swartz, J., Georgiou, G., (1998), "Expression of Active Human Tissue-Type Plasminogen Activator in Escherichia coli", Applied and Environmental Microbiology, Dec. 1998, 64:4891-4896, American Society for Microbiology, Washington, D.C., USA	

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	06/26/2006
-----------------------	---------------------------	--------------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
		Application Number	Unassigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	August 4, 2003
		First Named Inventor	Martin OPPER et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	38005-0183
(use as many sheets as necessary)			
Sheet	4	of	4

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KAC	A26	Wörn, A., and Plückthun, A., "An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly", FEBS Letters 427 (1998) 357-361, Federation of European Biochemical Societies, Amsterdam, Holland	
	A27	Wörn, A., Auf der Maur, A., Escher, D., Honegger, A., Barberis, A., and Plückthun, A., "Correlation between in Vitro Stability and in Vivo Performance of Anti-CGN4 Intrabodies as Cytoplasmic Inhibitors", (2000) The Journal of Biological Chemistry Vol. 275, No. 4, Issue of January 28, 2795-2803, American Society for Biochemistry and Molecular Biology, Baltimore, Maryland, USA	
	A28	PROBA et al., "Functional antibody single-chain fragments from the cytoplasm of Escherichia coli: influence of thioredoxin reductase", Gene, Vol. 159, No. 2, pp. 203-207,	1995
	A29	EMERY et al., "Strategies for Humanizing Antibodies" in Antibody Engineering, 2nd edition, Carol Borrebaeck, Ed., Oxford University Press, pp. 159-183	1995
	A30	BUCHNER et al., "A method for increasing the yield of properly folded recombinant fusion proteins", Anal Biochem, Vol. 205, pp. 263-270 ,	1992
	A31	HOCHMAN et al., Biochemistry, 1976, Vol. 15, pp. 2706-2710	
	A32	GOTO et al., Journal of Molecular Biology, 1982, Vol. 158, pp. 911-926	
↓	A33	SKERRA et al., 1988, Vol. 240, 1038-1043	

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	06/26/2006
--------------------	---------------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.